×
About 12 results

Current Evidence on Abuse and Misuse of Gabapentinoids.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686181
Drug Safety; Hägg S, Jönsson AK et. al.

Aug 28th, 2020 - This review summarizes current evidence on the abuse and misuse of the gabapentinoids pregabalin and gabapentin. Pharmacovigilance studies, register-based studies, surveys, clinical toxicology studies, and forensic toxicology studies were identified and scrutinized with the goal to define the problem, identify risk factors, and discuss possible methods to reduce the potenti...

Misuse and abuse of pregabalin and gabapentin: cause for concern?
https://doi.org/10.1007/s40263-014-0164-4
CNS Drugs; Schifano F

Apr 24th, 2014 - Gabapentinoids (e.g. pregabalin and gabapentin) are widely used in neurology, psychiatry and primary healthcare but are increasingly being reported as possessing a potential for misuse. In fact, increasing levels of both prescriptions and related fatalities, together with an anecdotally growing black market, have been reported from a range of countries. This article reviews the current e...

Abuse and Misuse of Pregabalin and Gabapentin.
https://doi.org/10.1007/s40265-017-0700-x
Drugs Evoy KE, Morrison MD et. al.

Feb 1st, 2017 - Gabapentinoid (pregabalin and gabapentin) abuse is increasingly being reported. To assess the extent of gabapentinoid abuse, characteristics of typical abusers, patterns of abuse, and potential harms in order to bring this trend to providers' attention. A systematic review of MEDLINE, Cochrane Library, ClinicalTrials.gov, and US FDA data, indexed through 28 July 2016...

Signs point to growing abuse of gabapentinoids in the U.S.
https://www.mdedge.com/neurology/article/175585/addiction-medicine/signs-point-growing-abuse-gabapentinoids-us
Michele G. Sullivan

Sep 25th, 2018 - LAS VEGAS – Up to 22% of opioid abusers also abuse gabapentin, taking high doses of the antiepileptic for its psychoactive effects, or to potentiate the effect of opioids. ah_designs/Getty Images The drug – the 10th most commonly prescribed in the United States – is increasingly implicated in overdose deaths.

Prevalence of and Factors Associated with Gabapentinoid Use and Misuse Among Tex...
https://doi.org/10.1007/s40261-021-01009-6 10.1056/NEJMp1704633 10.2147/RMHP.S168504 10.1007/s40122-018-0097-6 10.1001/jama.2014.18514 10.2165/11536200-000000000-00000 10.1080/14737175.2016.1202764 10.1111/1556-4029.14021 10.1007/s40263-016-0359-y 10.1016/j.sapharm.2018.06.018 10.1007/s40261-017-0530-3 10.3399/bjgp12X653516 10.1007/s40264-020-00985-6 10.1016/J.DRUGALCDEP.2018.01.018 10.1007/s40261-016-0421-z 10.1007/s00228-012-1464-6 10.1007/s00228-010-0853-y 10.1037/adb0000337 10.1176/appi.ajp.2014.14101272 10.1371/journal.pmed.1002396 10.7326/M18-1136 10.1016/j.drugalcdep.2017.01.01325 10.1111/bcp.13892 10.1111/bph.14219 10.1111/add.13843 10.1111/add.13324 10.1002/phar.2096 10.1080/02791072.2020.1802087 10.1016/j.forsciint.2018.01.025 10.1080/08897077.2019.1671943 10.18553/jmcp.2020.26.3.246 10.1007/s40265-020-01432-7
Clinical Drug Investigation; Ibiloye EA, Barner JC et. al.

Feb 13th, 2021 - Gabapentin and pregabalin have been considered relatively safe opioid-sparing adjuncts for pain management. However, rising prescribing trends, presence of gabapentinoids in opioid-related overdoses, and the growing body of evidence regarding gabapentinoid misuse and abuse, have caused gabapentinoids to emerge as a drug class of public health concern. This study aime...

Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update.
https://doi.org/10.1007/s40265-020-01432-7 10.1007/s40265-017-0700-x 10.2147/RMHP.S168504 10.1007/s00228-010-0853-y 10.1007/s40263-016-0359-y 10.1111/bcp.12277 10.1007/s40264-017-0595-1 10.1371/journal.pmed.1002396 10.7326/M18-1136 10.1016/j.drugalcdep.2017.01.013 10.1007/s11469-017-9813-4 10.1016/j.jsps.2018.01.012 10.1080/14659891.2018.1554716 10.1016/j.japh.2018.12.018 10.1002/pds.4230 10.1111/add.14412 10.5694/mja2.12036 10.1155/2016/9298571 10.1007/s40261-017-0616-y 10.1016/j.drugalcdep.2016.08.152 10.1111/bcp.13892 10.1111/1556-4029.13263 10.1016/j.sapharm.2018.06.018 10.1016/j.amepre.2018.12.009 10.1136/injuryprev-2016-042308 10.1111/add.14014 10.1002/dta.2347 10.1111/add.13843 10.1371/journal.pmed.1002965 10.4088/JCP.15l10296 10.1093/jat/bkz036 10.1007/s40261-017-0530-3 10.1002/phar.2096 10.1016/j.forsciint.2018.01.025 10.1016/j.drugalcdep.2018.04.025 10.1016/j.drugalcdep.2018.01.018 10.1016/j.drugalcdep.2018.09.019 10.1007/s40263-017-0467-3 10.1177/1078345817727730 10.1111/1556-4029.14021 10.4088/PCC.18m02291 10.1186/s13690-018-0254-8 10.1037/adb0000337 10.1111/ajad.12737 10.1080/14659891.2016.1235734 10.1080/14659891.2016.1271042 10.1016/j.therap.2016.04.006 10.1097/JCP.0000000000000983 10.1097/YCT.0000000000000475 10.1097/PRA.0000000000000403 10.1016/j.jpeds.2016.11.004 10.3109/15569527.2016.1141420 10.1093/jat/bkw129 10.1016/j.drugpo.2020.102752 10.1080/02791072.2020.1802087 10.1016/j.drugalcdep.2019.107554 10.1080/02791072.2020.1734695 10.1080/08897077.2019.1671943 10.1016/j.jpeds.2019.09.029 10.1016/j.bja.2020.05.017 10.1111/add.13324 10.1177/1060028015620800 10.2147/JEP.S124391 10.1016/j.euroneuro.2017.08.430 10.1136/bmj.l2147 10.1136/bmj.j3326 10.18553/jmcp.2002.8.4.266
Drugs Evoy KE, Sadrameli S et. al.

Nov 20th, 2020 - A 2017 systematic review (SR) identified 59 studies examining gabapentinoid (pregabalin and gabapentin) misuse/abuse. Evidence of gabapentinoid misuse/abuse has since grown substantially. Update previous SR and describe new insights regarding gabapentinoid abuse. A SR of PubMed was conducted to identify studies published from 7/29/2016-8/31/2020. Four searches...

A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's...
https://doi.org/10.1007/s40263-016-0359-y
CNS Drugs; Chiappini S, Schifano F

Jun 17th, 2016 - The gabapentinoids pregabalin and gabapentin are being increasingly prescribed for a range of clinical conditions. Recently, although gabapentinoids at therapeutic dosages may present with low addictive liability levels, cases of misuse and rising numbers of related fatalities have been reported. The aim of the study was to identify and assess cases of gabapentinoid misu...

The role of gabapentinoids in acute and chronic pain after surgery.
https://doi.org/10.1097/ACO.0000000000000767
Current Opinion in Anaesthesiology; Kumar AH, Habib AS

Jul 24th, 2019 - Gabapentinoid use has increased substantially in the past several years after initial promising data with regard to acute perioperative pain control. The purpose of this review is to critically appraise the evidence for the use of gabapentinoids for acute pain management and its impact on the development of chronic pain after surgery. Recent meta-analyses have revealed that prior data li...

Anticonvulsant With Opioids Tied To Higher Mortality
https://www.medpagetoday.com/neurology/painmanagement/74655

Aug 20th, 2018 - Action Points Treatment with pregabalin (Lyrica) was associated with an increased risk for opioid-related death when co-prescribed with opioids. Note that FDA reports suggest the number of patients receiving gabapentinoids with opioid analgesics or benzodiazepines has increased, with more than half of patients concurrently dispensed both a gabapentinoid and an opioid analgesic. Treatment...

Neurontin, Gralise, Horizant (gabapentin) and Lyrica, Lyrica CR (pregabalin): Drug Safety Communication - Serious Breathing Problems
http://www.fda.gov/safety/medical-product-safety-information/neurontin-gralise-horizant-gabapentin-and-lyrica-lyrica-cr-pregabalin-drug-safety-communication

[Posted 12/19/2019] AUDIENCE: Patient, Health Professional, Pharmacy ISSUE: FDA is warning that serious breathing difficulties may occur in patients using gabapentin (Neurontin, Gralise, Horizant) or pregabalin (Lyrica, Lyrica CR) who have respiratory risk factors. These include the use of opioid pain medicines and other drugs that depress the central nervous system, and conditions such as chro...

FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR)
http://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin

12-19-2019  FDA Drug Safety Communication What safety concern is FDA announcing? The U.S. Food and Drug Administration (FDA) is warning that serious breathing difficulties may occur in patients using gabapentin (Neurontin, Gralise, Horizant) or pregabalin (Lyrica, Lyrica CR) who have respiratory risk factors. These include the use of opioid pain medicines and other drugs that depress the centra...

Neurontin, Gralise, Horizant (gabapentin) and Lyrica, Lyrica CR (pregabalin): Drug Safety Communication - Serious Breathing Problems | FDA
https://www.fda.gov/safety/medical-product-safety-information/neurontin-gralise-horizant-gabapentin-and-lyrica-lyrica-cr-pregabalin-drug-safety-communication

[Posted 12/19/2019] AUDIENCE: Patient, Health Professional, Pharmacy ISSUE: FDA is warning that serious breathing difficulties may occur in patients using gabapentin (Neurontin, Gralise, Horizant) or pregabalin (Lyrica, Lyrica CR) who have respiratory risk factors. These include the use of opioid pain medicines and other drugs that depress the central nervous system, and conditions such as chro...